Related Experiment Video

Updated: Nov 6, 2025

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.1K

Potential Therapeutic Targets of Obesity-Related Glomerulopathy

Jiao He1, Yanxin Xiao1, Jun Wang1

  • 1Department of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, People's Republic of China.

Metabolic Syndrome and Related Disorders
|May 4, 2021
PubMed

Insights

Obesity-related glomerulopathy (ORG) treatments focus on weight loss and renin-angiotensin-aldosterone blockade for antiproteinuric effects. Emerging therapies targeting lipid metabolism show promise for ORG management.

Area of Science:

  • Nephrology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Rising global obesity rates correlate with an increasing incidence of obesity-related glomerulopathy (ORG).
  • ORG is a significant cause of chronic kidney disease in obese individuals.

Purpose of the Study:

  • To review potential therapeutic targets for ORG.
  • To explore the mechanisms of action for these therapies.
  • To highlight the importance of obesity and ORG prevention and treatment.

Main Methods:

  • Systematic identification of surveys, reports, and published studies.
  • Literature analysis of existing data on ORG therapies.

Main Results:

  • Weight loss and renin-angiotensin-aldosterone blockade are established therapies with antiproteinuric effects and can reverse hyperfiltration in ORG.
  • Glucagon-like peptide-1-based therapies have demonstrated improvements in proteinuria.
  • Novel therapies targeting lipid metabolism, including FXR, TGR5, and PPARα agonists, show therapeutic potential.

Conclusions:

  • Effective management strategies for ORG are crucial.
  • Further research into novel therapeutic targets for ORG is warranted.
  • Preventative measures against obesity are key to combating the ORG epidemic.
Keywords:
FXRGLP-1ORGRAASTGR5weight loss

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.9K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

218

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
516
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
14.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
43
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
788
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
63